Synonyms: CCX 354 | CCX-354 | CCX-354-C
Compound class:
Synthetic organic
Comment: CCX354 is an orally active CCR1 antagonist that was originally developed by Chemocentryx for anti-inflammatory/immunomodulatory potential. The chemical structure is claimed as Example 16 in patent WO2008147815A1 [1]. The structure in the patent resolves to PubChem CID 25016615, which is a tautomeric representation of the claimed structure.
|
|
References |
1. Li L, Pennell AMK, Zhang P. (2008)
3-(imidazolyl)-pyrazolo[3,4-b]pyridines. Patent number: WO2008147815A1. Assignee: Chemocentryx, Inc.. Priority date: 22/05/2007. Publication date: 04/12/2008. |
2. Tak PP, Balanescu A, Tseluyko V, Bojin S, Drescher E, Dairaghi D, Miao S, Marchesin V, Jaen J, Schall TJ et al.. (2013)
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis, 72 (3): 337-44. [PMID:22589376] |